[{"address1": "15440 Laguna Canyon Road", "address2": "Suite 160", "city": "Irvine", "state": "CA", "zip": "92618", "country": "United States", "phone": "949 409 1801", "website": "https://www.tarsusrx.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Tarsus Pharmaceuticals, Inc., a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease. It is developing TP-04 for the treatment of rosacea; and TP-05 for Lyme prophylaxis and community malaria reduction. In addition, the company develops lotilaner to address diseases across therapeutic categories in human medicine, including eye care, dermatology, and other infectious disease prevention. Tarsus Pharmaceuticals, Inc. was incorporated in 2016 and is headquartered in Irvine, California.", "fullTimeEmployees": 244, "companyOfficers": [{"maxAge": 1, "name": "Dr. Bobak R. Azamian M.D.", "title": "Co-Founder, President, CEO & Chairman", "fiscalYear": 2023, "totalPay": 1083000, "exercisedValue": 0, "unexercisedValue": 13324677}, {"maxAge": 1, "name": "Mr. Jeffrey S.  Farrow CPA", "age": 62, "title": "CFO & Chief Strategy Officer", "yearBorn": 1962, "fiscalYear": 2023, "totalPay": 722948, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Seshadri  Neervannan Ph.D.", "age": 56, "title": "Chief Operating Officer", "yearBorn": 1968, "fiscalYear": 2023, "totalPay": 759200, "exercisedValue": 0, "unexercisedValue": 3695880}, {"maxAge": 1, "name": "Mr. David  Nakasone", "title": "Head of Investor Relations", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Bryan  Wahl J.D., M.D.", "age": 46, "title": "General Counsel & Corporate Secretary", "yearBorn": 1978, "fiscalYear": 2023, "totalPay": 619087, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Adrienne  Kemp", "title": "Senior Director of Corporate Communications", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Matthew  Rossen M.B.A.", "age": 46, "title": "Vice President of Marketing", "yearBorn": 1978, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Scott  Youmans", "title": "Vice President of Sales", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Dianne C. Whitfield M.S.W.", "age": 47, "title": "Chief Human Resources Officer", "yearBorn": 1977, "fiscalYear": 2023, "totalPay": 578900, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Aziz  Mottiwala M.B.A.", "age": 46, "title": "Chief Commercial Officer", "yearBorn": 1978, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 7, "boardRisk": 7, "compensationRisk": 9, "shareHolderRightsRisk": 8, "overallRisk": 8, "governanceEpochDate": 1735689600, "compensationAsOfEpochDate": 1703980800, "maxAge": 86400, "priceHint": 2, "previousClose": 55.24, "open": 54.05, "dayLow": 51.935, "dayHigh": 54.38, "regularMarketPreviousClose": 55.24, "regularMarketOpen": 54.05, "regularMarketDayLow": 51.935, "regularMarketDayHigh": 54.38, "forwardPE": -26.477386, "volume": 799710, "regularMarketVolume": 799710, "averageVolume": 752018, "averageVolume10days": 785260, "averageDailyVolume10Day": 785260, "bid": 52.26, "ask": 52.96, "bidSize": 100, "askSize": 100, "marketCap": 2014175360, "fiftyTwoWeekLow": 20.082, "fiftyTwoWeekHigh": 57.14, "priceToSalesTrailing12Months": 15.538959, "fiftyDayAverage": 50.3203, "twoHundredDayAverage": 36.2939, "currency": "USD", "enterpriseValue": 1768932864, "profitMargins": -1.03643, "floatShares": 28973719, "sharesOutstanding": 38226900, "sharesShort": 7543047, "sharesShortPriorMonth": 7140778, "sharesShortPreviousMonthDate": 1731628800, "dateShortInterest": 1734048000, "sharesPercentSharesOut": 0.1973, "heldPercentInsiders": 0.087299995, "heldPercentInstitutions": 1.20692, "shortRatio": 12.17, "shortPercentOfFloat": 0.2045, "impliedSharesOutstanding": 38226900, "bookValue": 6.217, "priceToBook": 8.475148, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1727654400, "netIncomeToCommon": -134343008, "trailingEps": -3.75, "forwardEps": -2.16, "enterpriseToRevenue": 13.647, "enterpriseToEbitda": -12.684, "52WeekChange": 1.3303847, "SandP52WeekChange": 0.22263205, "exchange": "NMS", "quoteType": "EQUITY", "symbol": "TARS", "underlyingSymbol": "TARS", "shortName": "Tarsus Pharmaceuticals, Inc.", "longName": "Tarsus Pharmaceuticals, Inc.", "firstTradeDateEpochUtc": 1602855000, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EST", "uuid": "625f5f4c-434a-3f1f-ab4d-e1421a7e08c6", "messageBoardId": "finmb_650383665", "gmtOffSetMilliseconds": -18000000, "currentPrice": 52.69, "targetHighPrice": 84.0, "targetLowPrice": 41.0, "targetMeanPrice": 66.0, "targetMedianPrice": 68.0, "recommendationMean": 1.44444, "recommendationKey": "strong_buy", "numberOfAnalystOpinions": 9, "totalCash": 316952000, "totalCashPerShare": 8.291, "ebitda": -139458000, "totalDebt": 71708000, "quickRatio": 5.272, "currentRatio": 5.422, "totalRevenue": 129621000, "debtToEquity": 30.195, "revenuePerShare": 3.571, "returnOnAssets": -0.27263, "returnOnEquity": -0.59556, "grossProfits": 107200000, "freeCashflow": -71101504, "operatingCashflow": -100180000, "revenueGrowth": 24.718, "grossMargins": 0.82703, "ebitdaMargins": -1.07589, "operatingMargins": -0.52292, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2025-01-11"}]